Because of the high therapeutic potential of ERβ ligands, we should expect that in the coming years more ERβ-selective agonists will be launched in the market for the treatment of different pathologies such as breast cancer, prostate cancer, colorectal cancer, cardiovascular diseases, and neurodegenerative diseases. The gene discussed is ESR2; the disease is prostate cancer.